Improving glycemic and cholesterol control through an integrated approach incorporating colesevelam – a clinical perspective
Ronald B GoldbergDivision of Endocrinology, Diabetes and Metabolism, Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL, USAAbstract: Bile sequestrants have been used for almost 50 years to lower low density lipoprotein cholesterol (LDL-C). The advent of colesevela...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2009
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/0d5d94d5830a49bf805e8e05cf3fe83a |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:0d5d94d5830a49bf805e8e05cf3fe83a |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:0d5d94d5830a49bf805e8e05cf3fe83a2021-12-02T04:19:49ZImproving glycemic and cholesterol control through an integrated approach incorporating colesevelam – a clinical perspective1178-7007https://doaj.org/article/0d5d94d5830a49bf805e8e05cf3fe83a2009-05-01T00:00:00Zhttp://www.dovepress.com/improving-glycemic-and-cholesterol-control-through-an-integrated-appro-a3089https://doaj.org/toc/1178-7007Ronald B GoldbergDivision of Endocrinology, Diabetes and Metabolism, Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL, USAAbstract: Bile sequestrants have been used for almost 50 years to lower low density lipoprotein cholesterol (LDL-C). The advent of colesevelam in 2000 provided a more tolerable add-on LDL-C-lowering agent with an excellent safety record and with likely benefit for coronary heart disease events. Colesevelam lowers LDL-C approximately 15%, and has an additive effect when combined with statin or non-statin lipid-modifying agents. It also tends to increase triglyceride levels. The discovery that bile sequestrants also lower glucose levels led to definitive large-scale clinical trials testing the effect of colesevelam as a dual antihyperglycemic agent with LDL-C-lowering properties in type 2 diabetic subjects on metformin-, sulfonylurea- or insulin-based therapy with inadequate glycemic control. Colesevelam was found to lower hemoglobin A1c (HbA1c) by approximately 0.5% compared to placebo over the 16- to 26-week period, and had similar effects on the lipid profile in these diabetic subjects, as had previously been demonstrated in non-diabetic individuals. Colesevelam was well tolerated, with constipation being the most common adverse effect, and did not cause weight gain or excessive hypoglycemia. Colesevelam thus combines antihyperglycemic action with LDL-C-lowering properties, and should be useful in the management of type 2 diabetes.Keywords: colesevelam, treatment, hyperglycemia, LDL-cholesterol Ronald B GoldbergDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2009, Iss default, Pp 11-21 (2009) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Specialties of internal medicine RC581-951 |
| spellingShingle |
Specialties of internal medicine RC581-951 Ronald B Goldberg Improving glycemic and cholesterol control through an integrated approach incorporating colesevelam – a clinical perspective |
| description |
Ronald B GoldbergDivision of Endocrinology, Diabetes and Metabolism, Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL, USAAbstract: Bile sequestrants have been used for almost 50 years to lower low density lipoprotein cholesterol (LDL-C). The advent of colesevelam in 2000 provided a more tolerable add-on LDL-C-lowering agent with an excellent safety record and with likely benefit for coronary heart disease events. Colesevelam lowers LDL-C approximately 15%, and has an additive effect when combined with statin or non-statin lipid-modifying agents. It also tends to increase triglyceride levels. The discovery that bile sequestrants also lower glucose levels led to definitive large-scale clinical trials testing the effect of colesevelam as a dual antihyperglycemic agent with LDL-C-lowering properties in type 2 diabetic subjects on metformin-, sulfonylurea- or insulin-based therapy with inadequate glycemic control. Colesevelam was found to lower hemoglobin A1c (HbA1c) by approximately 0.5% compared to placebo over the 16- to 26-week period, and had similar effects on the lipid profile in these diabetic subjects, as had previously been demonstrated in non-diabetic individuals. Colesevelam was well tolerated, with constipation being the most common adverse effect, and did not cause weight gain or excessive hypoglycemia. Colesevelam thus combines antihyperglycemic action with LDL-C-lowering properties, and should be useful in the management of type 2 diabetes.Keywords: colesevelam, treatment, hyperglycemia, LDL-cholesterol |
| format |
article |
| author |
Ronald B Goldberg |
| author_facet |
Ronald B Goldberg |
| author_sort |
Ronald B Goldberg |
| title |
Improving glycemic and cholesterol control through an integrated approach incorporating colesevelam – a clinical perspective |
| title_short |
Improving glycemic and cholesterol control through an integrated approach incorporating colesevelam – a clinical perspective |
| title_full |
Improving glycemic and cholesterol control through an integrated approach incorporating colesevelam – a clinical perspective |
| title_fullStr |
Improving glycemic and cholesterol control through an integrated approach incorporating colesevelam – a clinical perspective |
| title_full_unstemmed |
Improving glycemic and cholesterol control through an integrated approach incorporating colesevelam – a clinical perspective |
| title_sort |
improving glycemic and cholesterol control through an integrated approach incorporating colesevelam – a clinical perspective |
| publisher |
Dove Medical Press |
| publishDate |
2009 |
| url |
https://doaj.org/article/0d5d94d5830a49bf805e8e05cf3fe83a |
| work_keys_str_mv |
AT ronaldbgoldberg improvingglycemicandcholesterolcontrolthroughanintegratedapproachincorporatingcolesevelamampndashaclinicalperspective |
| _version_ |
1718401292184846336 |